Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years.

BACKGROUND The epidemiologic trends of hepatitis B virus (HBV) infection in human immunodeficiency virus (HIV)-infected patients over the past 20 years are largely unknown. METHODS Prevalence and risk factors for HBV infection overall, at the time of HIV infection, and after HIV infection were examined in an ongoing observational HIV cohort study. Risk factors for HBV infection at the time of diagnosis of HIV infection were evaluated using logistic regression, and risk of incident HBV infection after diagnosis of HIV infection was evaluated using Cox proportional hazards models. RESULTS Of the 2769 evaluable participants, 1078 (39%) had HBV infection, of whom 117 (11%) had chronic HBV infection. The yearly cross-sectional prevalence of HBV infection decreased from a peak of 49% in 1995 to 36% in 2008 (P < .001). The prevalence of HBV infection at the time of diagnosis of HIV infection decreased during 1989-2008 from 34% to 9% (P < .001). The incidence of HBV infection after diagnosis of HIV infection decreased from 4.0 cases per 100 person-years during the pre-highly active antiretroviral therapy (HAART) era to 1.1 cases per 100 person-years during the HAART era (P < .001); however, this incidence remained unchanged during 2000-2008 (P = .49), with >20% of HBV infections occurring after HIV infection being chronic. Decreased risk of HBV infection after diagnosis of HIV infection was associated with higher CD4 cell count and the use of HBV-active HAART. Receipt of 1 dose of HBV vaccine was not associated with reduced risk of HBV infection after diagnosis of HIV infection. CONCLUSIONS Although the burden of HBV infection overall is slowly decreasing among HIV-infected individuals, the persistent rate of HBV infection after diagnosis of HIV infection raises concern that more-effective prevention strategies may be needed to significantly reduce the prevalence of HBV infection in this patient population.

[1]  Helen M. Chun,et al.  Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals , 2010, AIDS.

[2]  A. Mocroft,et al.  Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Jennifer S. Lin,et al.  Behavioral Counseling to Prevent Sexually Transmitted Infections: A Systematic Review for the U.S. Preventive Services Task Force , 2008, Annals of Internal Medicine.

[4]  M. Roediger,et al.  Increasing Age at HIV Seroconversion From 18 to 40 Years Is Associated With Favorable Virologic and Immunologic Responses to HAART , 2008, Journal of acquired immune deficiency syndromes.

[5]  V. Soriano,et al.  Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. , 2008, AIDS.

[6]  M. Sulkowski.  Management of hepatic complications in HIV-infected persons. , 2008, The Journal of infectious diseases.

[7]  J. Kao,et al.  Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  S. Berman,et al.  Trends in primary and secondary syphilis among men who have sex with men in the United States. , 2007, American journal of public health.

[9]  L. Finelli,et al.  Surveillance for acute viral hepatitis--United States, 2005. , 2007, Morbidity and mortality weekly report. Surveillance summaries.

[10]  W. Kim.  Epidemiology of hepatitis B in the United States , 2007, Hepatology.

[11]  M. Landrum,et al.  Liver-Related Complications in HIV-Infected Individuals , 2007 .

[12]  O. Kirk,et al.  Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. , 2006, Archives of internal medicine.

[13]  B. Santos,et al.  [Ambulatorial prevalence of hepatitis B and C markers in patients with human immunodeficiency virus infection in a general hospital]. , 2006, Arquivos de gastroenterologia.

[14]  M. Wallace,et al.  Incidence and risk factors for the occurrence of non‐AIDS‐defining cancers among human immunodeficiency virus‐infected individuals , 2005, Cancer.

[15]  A. Mocroft,et al.  Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort , 2005, AIDS.

[16]  A. Vibhagool,et al.  Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study. , 2004, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[17]  S. Cole,et al.  Association between syphilis, antibodies to herpes simplex virus type 2, and recreational drug use and hepatitis B virus infection in the Women's Interagency HIV Study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  J. Parsons,et al.  Prevention With HIV-Seropositive Men Who Have Sex With Men: Lessons From the Seropositive Urban Men’s Study (SUMS) and the Seropositive Urban Men’s Intervention Trial (SUMIT) , 2004, Journal of acquired immune deficiency syndromes.

[19]  J. Mascola,et al.  Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort , 2003, AIDS.

[20]  A. McNaghten,et al.  Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. , 2003, The Journal of infectious diseases.

[21]  COST-EFFECTIVENESS IMPLICATIONS OF THE TIMING OF ANTIRETROVIRAL THERAPY IN HIV-INFECTED ADULTS , 2002 .

[22]  H. Margolis,et al.  Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. , 2002, The Journal of infectious diseases.

[23]  R. Chaisson,et al.  Hepatotoxicity associated with nevirapine or efavirenz‐containing antiretroviral therapy: Role of hepatitis C and B infections , 2002, Hepatology.

[24]  P. Reiss,et al.  Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection , 2000, AIDS.

[25]  A. Moscicki,et al.  Seroprevalence and Risk Factors of Hepatitis B, Hepatitis C, and Human Cytomegalovirus Among HIV‐Infected and High‐Risk Uninfected Adolescents: Findings of the REACH Study , 2000 .

[26]  R. Chaisson,et al.  Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. , 2000, JAMA.

[27]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[28]  M. Manns,et al.  Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. , 1997, Journal of hepatology.

[29]  P. Couzigou,et al.  Prevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus infection in patients with HIV infection in Aquitaine , 1996 .

[30]  M. Thomas,et al.  Antiretroviral treatment of HIV infection. , 1995, The New Zealand medical journal.

[31]  John W. Ward,et al.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[32]  W. Cleveland.  Robust Locally Weighted Regression and Smoothing Scatterplots , 1979 .

[33]  S. Hammer,et al.  Antiretroviral Treatment of Adult HIV Infection 2008 Recommendations of the International AIDS Society–USA Panel , 2008 .

[34]  R. Bruno,et al.  Natural history of chronic hepatitis B in co-infected patients. , 2006, Journal of hepatology.

[35]  Incidence of acute hepatitis B--United States, 1990-2002. , 2004, MMWR. Morbidity and mortality weekly report.

[36]  Incorporating HIV prevention into the medical care of persons living with HIV. Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. , 2003, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[37]  M. Glick,et al.  HIV-Infected Patients , 2001 .

[38]  L. Levin,et al.  Seroprevalence and risk factors of hepatitis B, hepatitis C, and human cytomegalovirus among HIV-infected and high-risk uninfected adolescents: findings of the REACH Study. Adolescent Medicine HIV/AIDS Research Network. , 2000, Sexually transmitted diseases.

[39]  Références , 2022, Revue annuelle du marché des produits forestiers 2019-2020.